Soleno Therapeutics to Participate in Upcoming Conferences
Rhea-AI Summary
Soleno Therapeutics (NASDAQ: SLNO) will participate in three investor conferences in Feb–Mar 2026: Guggenheim Emerging Outlook: Biotech Summit, Oppenheimer 36th Annual Healthcare Life Sciences Conference, and TD Cowen 46th Annual Health Care Conference.
Presentations are scheduled Feb 12 (11:30 AM ET, fireside chat), Feb 26 (10:00 AM ET, company presentation) and Mar 4 (9:50 AM ET, fireside chat). Webcasts and replays will be available in the company’s Investors section at www.soleno.life.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
SLNO was down 3.61% pre-news. Key biotech peers also traded lower: IMVT -2.76%, VKTX -3.43%, RARE -2.08%, SRRK -1.71%, MLYS -1.13%, but no peers appeared in the momentum scanner and there were no same-day peer headlines.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | Prelim 2025 results | Positive | -3.4% | Preliminary 2025 revenues, VYKAT XR launch metrics, profitability and cash update. |
| Jan 05 | Pivotal study data | Positive | -4.1% | Publication of pivotal VYKAT XR randomized withdrawal data in PWS patients. |
| Dec 03 | Board member passing | Negative | +3.9% | Announcement of audit chair’s passing and expected change in committee leadership. |
| Nov 24 | Conference appearance | Neutral | +1.8% | Planned CEO fireside chat at a major healthcare investor conference. |
| Nov 11 | ASR buyback | Positive | +5.2% | $100M accelerated share repurchase following achievement of profitability in Q3 2025. |
Recent history shows several instances where positive operational or clinical updates were followed by negative price reactions, while capital return (ASR) and neutral events sometimes coincided with gains.
Over the last few months, Soleno reported preliminary unaudited 2025 results tied to the U.S. launch of VYKAT XR, with expected full-year net revenue of $189M–$191M and profitability supported by ~$500M in year-end cash and securities (Jan 12, 2026). Earlier, pivotal VYKAT XR data in Prader-Willi syndrome were published in a major journal (Jan 5, 2026). The company also announced a $100M accelerated share repurchase (Nov 11, 2025). Today’s conference-participation news fits the pattern of regular investor-relations activity following these operational and capital deployment milestones.
Market Pulse Summary
This announcement details Soleno’s participation in three upcoming investor conferences in February and March, including sessions at Guggenheim, Oppenheimer, and TD Cowen with scheduled presentation times. It follows recent milestones such as preliminary 2025 VYKAT XR revenue of $189M–$191M, profitability, and a $100M accelerated share repurchase. Investors tracking the story may watch how management commentary at these events updates on launch metrics, capital deployment, and any follow-up to recently filed executive compensation changes.
AI-generated analysis. Not financial advice.
REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in February and March:
Guggenheim Emerging Outlook: Biotech Summit 2026
Presentation Date: Thursday, February 12, 2026 at 11:30 AM ET
Presentation Format: Fireside Chat
Webcast: Here
Oppenheimer 36th Annual Healthcare Life Sciences Conference
Presentation Date: Thursday, February 26, 2026 at 10:00 AM ET
Presentation Format: Company presentation
TD Cowen 46th Annual Health Care Conference
Presentation Date: Wednesday, March 4, 2026 at 9:50 AM ET
Presentation Format: Fireside Chat
Webcast: Here
Replay of the Guggenheim and TD Cowen events will be available in the Investors section on the Company’s website at www.soleno.life.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s first commercial product, VYKAT™ XR (diazoxide choline) extended-release tablets, formerly known as DCCR, is a once-daily oral treatment for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome and was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025. For more information, please visit www.soleno.life.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
FAQ
When will Soleno Therapeutics (SLNO) present at the Guggenheim Biotech Summit in 2026?
What time and format is the SLNO presentation at Oppenheimer 36th Annual Healthcare Life Sciences Conference?
How can investors access Soleno Therapeutics' (SLNO) TD Cowen conference presentation replay?
Which Soleno (SLNO) conference presentations in Feb–Mar 2026 are fireside chats versus company presentations?
Where will Soleno Therapeutics (SLNO) post webcasts and replays for its February–March 2026 conferences?
